Dextroamphetamine controlled release - Cingulate Therapeutics

Drug Profile

Dextroamphetamine controlled release - Cingulate Therapeutics

Alternative Names: CTX-1302; Dextroampfetamine

Latest Information Update: 22 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cingulate Therapeutics
  • Class Amphetamines
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Attention-deficit hyperactivity disorder

Most Recent Events

  • 15 Jan 2018 Cingulate plans to pursue approval via the accelerated 505(b) regulatory pathway for Attenstion-deficit hyperactivity disorder in Q 018 (9313
  • 09 Jan 2018 Cingulate Therapeutics plans to file an IND application with the US FDA for Attention deficit hyperactivity disorder in Q2 2018
  • 09 Jan 2018 Cingulate Therapeutics plans a phase I/II trial for Attention deficit hyperactivity disorder in USA, in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top